Mastering Oncology Clinical Trials: Immune Checkpoint Inhibitors in Frontline Metastatic Non–Small Cell Lung Cancer

This activity was originally broadcast in conjunction with the 2023 ASHP Midyear conference.

Program Description
Non–small cell lung cancer (NSCLC) accounts for a large percentage of lung cancers diagnosed in the United States. The introduction of immune checkpoint inhibitors (ICIs) has provided additional treatment options beyond the first-line setting, and these agents have become the new standard of care. Oncology pharmacists must be equipped to interpret and apply the results of clinical trials of ICIs to ensure their safe and effective use in the treatment of patients with NSCLC. ICIs have demonstrated increased survival rates for patients with NSCLC, but these agents are also associated with immune-related adverse effects. This program will present clinical trial outcomes that have contributed to evidence-based recommendations for the use of ICIs in NSCLC. The role of the oncology pharmacist in managing treatment-related adverse effects with ICIs and developing personalized treatment and management plans for patients with NSCLC will be examined. 

Target audience: Health-system pharmacists, oncology pharmacists

Type of activity: Application
Release date: December 18, 2023
Expiration date: December 18, 2024

Time to complete activity: 1.5 hours

Learner level: Foundational, Intermediate

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze current treatment guidelines for the use of immune checkpoint inhibitors (ICIs) as frontline therapy in the management of metastatic non–small cell lung cancer (NSCLC)
• Examine the safety, efficacy, and clinical relevance of frontline ICI use in metastatic NSCLC based on the results of clinical trials
• Apply the findings from clinical trials on ICI use as frontline therapy in metastatic NSCLC to personalized treatment plans for individual patients
• Identify strategies for managing immune-mediated endocrinopathies associated with ICI-based therapies to optimize patient outcomes and minimize treatment-related toxicities

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-23-453-H01-P. The activity is available for CE credit through December 18, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Amanda S. Cass, PharmD, BCPS, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: GI Therapeutics, Takeda, Regeneron

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Shelby Merchant, PharmD, BCOP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Namissa-Buszka, PharmD, BCPS, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta, and Rebecca Green.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms